HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Decline in pulmonary function in patients with breast cancer receiving dose-dense chemotherapy: a prospective study.

AbstractBACKGROUND:
Prompted by complaints of dyspnea in breast cancer patients receiving adjuvant dose-dense chemotherapy (DDC), we sought to evaluate the possible association of DDC with pulmonary dysfunction.
PATIENTS AND METHODS:
A total of 34 consecutive patients receiving adjuvant DDC were enrolled. The chemotherapy regimen consisted of i.v. doxorubicin 60 mg/m(2) and cyclophosphamide 600 mg/m(2) (AC) every 14 days x4 with growth factor support followed by weekly i.v. paclitaxel 80 mg/m(2) x12. The following parameters were prospectively measured before and after the AC protocol (P1, P2) and at completion of paclitaxel treatment (P3): presence of dyspnea, blood pressure, pulse rate, hemoglobin, erythrocyte sedimentation rate, C-reactive protein level, cardiac ejection fraction, and pulmonary function. Repeated measures analysis was used to evaluate differences among the time points, and paired t-test was used to evaluate differences between consecutive time points.
RESULTS:
Although only five patients (15%) complained of dyspnea, there was a significant decrease in mean carbon monoxide diffusing capacity (DLCO), in all patients from P1 (22.09 ml/min/mmHg) to P3 (15 ml/min/mmHg) and in 29 of 32 patients (90.6%) from P1 to P2 (15.96 ml/min/mmHg) (P<0.001).
CONCLUSIONS:
DDC is associated with a statistical significant reduction in DLCO. Awareness of this potential toxicity may be important in women with preexisting lung disease.
AuthorsR Yerushalmi, M R Kramer, S Rizel, A Sulkes, K Gelmon, T Granot, V Neiman, S M Stemmer
JournalAnnals of oncology : official journal of the European Society for Medical Oncology (Ann Oncol) Vol. 20 Issue 3 Pg. 437-40 (Mar 2009) ISSN: 1569-8041 [Electronic] England
PMID19139179 (Publication Type: Journal Article)
Topics
  • Aged
  • Breast Neoplasms (drug therapy, physiopathology)
  • Dose-Response Relationship, Drug
  • Humans
  • Prospective Studies
  • Respiratory Function Tests

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: